Biopharma & Life Sciences
Brainstorm Cell Therapeutics, Inc. Executive Compensation (FY24)
BCLI · Executive and director compensation, fiscal 2022 to 2024
Chief executive, fiscal 2024 ◇ Chaim Lebovits |
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
The Brainstorm Cell Therapeutics, Inc. brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Data as of October 28, 2026Latest filing (DEF 14A): May 16, 2025
2 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
69 figures on this page, cited to the filing that reported them. See the citations
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Chaim Lebovits: $1,128,795 → $750,303 (33.5% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Brainstorm Cell Therapeutics, Inc.'s chief executive and what were they paid?
Chaim Lebovits, Chief Executive Officer & President, received $750,303 in total compensation for fiscal 2024. Lebovits' total moved 33.5% lower from the $1,128,795 reported for fiscal 2023.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Chaim Lebovits President & Chief Executive Officer | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Stacy Lindborg Co-Chief Executive Officer | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Ralph Kern Former President & Former Chief Medical Officer Departed during or after this year | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Chaim Lebovits Chief Executive Officer & President | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Stacy Lindborg Former Co-Chief Executive Officer | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Uri Yablonka Executive Vice President, Chief Business Officer, Secretary and Director | ◇ | — | — | — | — | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Chaim Lebovits Chief Executive Officer & President | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Ibrahim Dagher Executive Vice President, Chief Medical Officer | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Stacy Lindborg Former Co-Chief Executive Officer Departed during or after this year | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Uri Yablonka Executive Vice President, Chief Business Officer, Secretary and Director | ◇ | — | ◇ | — | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2022
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Chaim Lebovits | OPTION | ◇ | — | — | ◇ | — | ◇ | — |
| Ralph Kern | RSA | — | — | — | ◇ | — | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Chaim Lebovits | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Stacy Lindborg | RSU | ◇ | ◇ | — | — |
| Ibrahim Dagher | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 08/01/2033 | |
| Uri Yablonka | RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2024
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Dr. Menghisteab Bairu | ◇ | — | — | — | — | — | ◇ |
Dr. Anthony Polverino, Mr. Nir Naor, Dr. Irit Arbel, Prof. Jacob Frenkel, Dr. Stacy Lindborg and Mr. Uri Yablonka served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Chaim Lebovits (Chief Executive Officer & President), FY2024 total compensation $750,303 (base salary $387,500) [exec_comp, SEC accession 0001104659-25-049785, filed 2025-05-16]What this page does not include
Everything above is a fact Brainstorm Cell Therapeutics, Inc. disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
69 figures on this page, cited to the filing that reported them.
69 cited to the filing
Documents cited
- 0001104659-25-049785COMPENSATION OF DIRECTORS
- 0001104659-23-115829
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Brainstorm Cell Therapeutics, Inc. executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/BCLI (accessed 2026).
Short form: data: Velarion
The Brainstorm Cell Therapeutics, Inc. brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
2 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Brainstorm Cell Therapeutics, Inc. and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}